Heron Therapeutics will host a conference call on August 10, 2026, to discuss Q2 financial results and business updates.
Quiver AI Summary
Heron Therapeutics, Inc. announced a conference call and live webcast scheduled for August 10, 2026, at 8:30 a.m. ET to discuss its second quarter financial results and recent business developments. Participants can join by phone using a provided registration link or via webcast on the company's website, where an archive will be available for 60 days post-call. Heron Therapeutics is a biotechnology company dedicated to developing innovative therapies aimed at improving patient care in acute care and oncology. The press release also includes a caution regarding forward-looking statements, highlighting the inherent risks and uncertainties in their projections.
Potential Positives
- Heron Therapeutics is hosting a conference call to report their second quarter financial results, indicating transparency and commitment to keeping investors informed.
- The live webcast format and availability of an archive for 60 days demonstrate the company's intent to reach a broad audience and provide access to important information.
- The company highlights its focus on improving patients' lives through innovative therapeutic developments, showcasing its mission and potential impact in healthcare.
- Heron's emphasis on having a portfolio of products that aim to advance standard-of-care for acute care and oncology patients presents potential market growth opportunities.
Potential Negatives
- None
FAQ
When is the Heron Therapeutics conference call scheduled?
The conference call is scheduled for Monday, August 10, 2026, at 8:30 a.m. ET.
How can I access the Heron Therapeutics conference call?
Participants can access the call via a registration link that provides dial-in details or through a live webcast on Heron’s website.
Where can I find the webcast of the conference call?
The webcast will be available under the Investor Relations section of Heron's website at www.herontx.com.
Will there be a recording of the conference call?
Yes, an archive of the teleconference and webcast will be available on Heron’s website for 60 days following the call.
What does Heron Therapeutics specialize in?
Heron Therapeutics is focused on developing and commercializing therapeutic innovations for improving medical care in acute care and oncology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HRTX Revenue
$HRTX had revenues of $34.7M in Q1 2026. This is a decrease of -26.71% from the same period in the prior year.
You can track HRTX financials on Quiver Quantitative's HRTX stock page.
You can access data on HRTX stock through the Quiver Quantitative API.
$HRTX Hedge Fund Activity
We have seen 69 institutional investors add shares of $HRTX stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 10,239,225 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,192,403
- ORBIMED ADVISORS LLC added 9,816,940 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,854,533
- CONGRESS PARK CAPITAL LLC removed 2,016,290 shares (-50.0%) from their portfolio in Q2 2026, for an estimated $860,552
- JANE STREET GROUP, LLC removed 1,367,891 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,094,449
- CITADEL ADVISORS LLC removed 1,335,776 shares (-63.8%) from their portfolio in Q1 2026, for an estimated $1,068,754
- PALE FIRE CAPITAL SE added 1,246,673 shares (+84.8%) to their portfolio in Q1 2026, for an estimated $997,463
- RICHMOND BROTHERS, INC. added 864,587 shares (+151.1%) to their portfolio in Q1 2026, for an estimated $691,756
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com . An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com .
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
